openPR Logo
Press release

Anti-Hypertensive Drugs Market Size, Share, Impressive Industry Growth, Analysis Report 2029

03-15-2023 02:55 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Orion Market Research

Anti-Hypertensive Drugs Market Size, Share, Impressive

The global anti-hypertension drugs market is estimated to grow at a CAGR of over 4% during the forecast period. Hypertension is a common condition among patients with diabetes. Hence, the adoption of anti-hypertensive is high among the diabetic population for the treatment of hypertension. Hence, the increased diabetic population coupled with the adoption of anti-hypertensive drugs is anticipated to drive the anti-hypertensive drug market industry significantly. Additionally, Angiotensin-converting enzyme (ACE) inhibitors manufactured by companies such as Novartis AG and Pfizer Inc. are the most used anti-hypertensive drugs by diabetic patients.

To learn more about this report request a sample copy @

Furthermore, hypertension is a major risk factor for patients suffering from conditions such as atherosclerotic cardiovascular disease (ASCVD), heart failure, and microvascular complications. ASCVD is considered to be a leading cause of morbidity and mortality in patients with diabetes. In recent years, numerous studies have shown that anti-hypertensive drug therapy can aid in significantly reducing ASCVD events. Along with ASCVD, anti-hypertensive drugs can aid in conditions such as heart failure, and microvascular complications in diabetic patients. Hence, the positive effects of anti-hypertensive drugs on ASCVD and other conditions are anticipated to drive the anti-hypertensive drugs market growth considerably during the forecast period.

Additionally, anti-hypertensive drug-based treatment can be given to the patient either as monotherapy or in suitable combinations. In addition to this, anti-hypertensive drugs also shows good outcomes when used for non pharmacological treatment such as low salt diet, weight loss, exercise, in diabetic patients which impact the anti-hypertensive drug market. Moreover, various government organizations across the globe are involved in the study of hypertension in diabetic patients that have also suggested the use of anti-hypertensive drugs in their guidelines, which in turn, is expected to expand the anti-hypertensive drug market size.

For instance, in the guidelines from European Society of Hypertension (ESH) and European Society of Cardiology, the use of drugs such as thiazide diuretics, ?-blockers, calcium channel blockers (CCBs), ACEis and angiotensin II receptor blockers (ARBs) are recommended for the initiation and maintenance of hypertension in diabetic patients. The drugs recommended in guidelines are anti-hypertensive drugs that are preferred to be used mostly in diabetic patients. Therefore, the guidelines from ESH and European Society of Cardiology, regarding the use of anti-hypertensive drugs are expected to drive the anti-hypertensive drugs market growth significantly during the forecasted period.

Anti-Hypertensive Drugs Market- Segmentation

By Drug Class

Thiazide Diuretics
Calcium Channel Blockers
ACE Inhibitors
Angiotensin II Receptor Antagonists (ARBS)

A full report of Global Anti-Hypertensive Drugs Market is available at:

Global Anti-Hypertensive Drugs Market- Segment by Region

North America

United States


United Kingdom
Rest of Europe


Rest of Asia-Pacific

Rest of the World

Middle East & Africa
Latin America

Company Profiles

AstraZeneca PLC
Bayer AG
Boehringer Ingelheim International GmbH
Daiichi Sankyo Co., Ltd.
Johnson & Johnson Services, Inc.
Lupin Ltd.
Merck KGaA
Noden Pharma DAC
Novartis International AG
Pfizer Inc.
Ranbaxy Laboratories Ltd.
Renata Ltd.
Sanofi S.A.
Sun Pharmaceuticals LLC
Takeda Pharmaceutical Company Ltd.
Teva Pharmaceutical Industries Ltd.
Unichem Laboratories Ltd.
United Therapeutics Corp.

Reasons to Buying From us -

We cover more than 15 major industries, further segmented into more than 90 sectors.
More than 120 countries are for analysis.
Over 100+ paid data sources mined for investigation.
Our expert research analysts answer all your questions before and after purchasing your report.

Visit more report at

Media Contact:

Contact Person: Mr. Anurag Tiwari
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Anti-Hypertensive Drugs Market Size, Share, Impressive Industry Growth, Analysis Report 2029 here

News-ID: 2976727 • Views: 799

More Releases from Orion Market Research

North American 3D Cell Culture Market Trends, Segmentation, Growth, Analysis and …
The North American 3D cell culture market is expected to witness a significant growth with the CAGR of 13.3% during the forecast period. The North American market for 3D cell culture is a significant market and is analyzed on the basis of the country such as the US and Canada. North American 3D Cell Culture Market reports provides us with a complete outlook on thorough assessment of thorough data about
European Diagnostic Biomarker Market Share, Trends, Future Outlook, Analysis and …
The European diagnostic biomarker market is estimated to grow significantly at a CAGR of more than 11% during the forecast period. Factors that are contributing significantly in the market growth include the presence of a well-developed healthcare sector and considerably high healthcare expenditure and infrastructure in its economies such as Germany, UK, France and many more. European Diagnostic Biomarker Market reports provides us with a complete outlook on thorough assessment
European Biological Sample Handling Market Size, Share, Growth, Analysis and For …
The European biological sample handling market is forecast to grow at a CAGR of around 8.4% during the forecast period. Europe is expected to share significantly in the global biological sample handling market owing to the well-developed healthcare sector, and significant research in the field of geniomics and protecomics in its economies such as UK, Germany, Italy, Spain and many more. European Biological Sample Handling Market reports provides us with
Asia-Pacific Biological Sample Handling Market Size, Share, Growth, Analysis and …
Asia-Pacific Biological Sample Handling market is expected to grow at CAGR of around 9.3% during the forecast period. Asia-Pacific is estimated to be a potential market for biological sample handling due to the increasing R&D and investments by government organizations in life science research. Asia-Pacific Biological Sample Handling Market reports provides us with a complete outlook on thorough assessment of thorough data about vital feature of the global industry related

All 5 Releases

More Releases for Drug

Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. Alcohol abuse and drug
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.  Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June. The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug